$4.50
-0.22%Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Wall Street analysts project that LXEO stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 18.33, with estimates ranging from a low of 10.00 to a high of 25.00.
The consensus 1-year price target stands at 18.33, with estimates ranging from a low of 10.00 to a high of 25.00.
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
High uncertainty. Very wide target spread indicates significant disagreement among analysts—major valuation uncertainty or transformation underway.
High uncertainty: Wide dispersion indicates analysts struggle to agree on valuation—proceed with caution and independent analysis.
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Wide estimate range reveals significant forecast uncertainty and potential volatility.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
High forecast uncertainty: Wide estimate range indicates analysts struggling to predict outcomes—suggests elevated risk and potential volatility.
Solid growth trajectory indicates healthy business performance and competitive positioning.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Wide estimate range reveals significant forecast uncertainty and potential volatility.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
High forecast uncertainty: Wide estimate range indicates analysts struggling to predict outcomes—suggests elevated risk and potential volatility.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
Significant contraction projected—major business challenges or industry disruption likely.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
During the last 12 months, insiders have purchased $685K and sold $495K worth of LXEO shares, resulting in $190K of net buying activity.
0
0.00
59.6K
336.67K
-337K
-$337K
0
0.00
13.2K
84.22K
-84K
-$84K
2.2K
5.80K
3.7K
34.31K
-29K
-$29K
162.5K
679.24K
7.8K
39.89K
+639K
+$639K
Cooperstone Brenda
Director
$105K
Cholmondeley Paula H
Director
$105K
Altschuler Steven
Director
$105K
Agger Mette Kirstine
Director
$105K
Diaz Reinaldo M
Director
$105K
Townsend Richard Nolan
Director, Officer: Chief Executive Officer
$420K
Otero Jose Manuel
Officer: Chief Operating Officer
$53K
Adler Eric
Officer: Chief Medical Officer
$9K
Robertson Jenny
Officer: Chief Legal Officer
$8K
See Tai Sandi
Officer: Chief Development Officer
$6K
Moderately bullish with $190K net buying. Insiders show cautious optimism through measured share purchases.
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
Broad-based insider buying: When multiple insiders independently decide to purchase shares, it often reflects genuine confidence rather than coordinated optics. This pattern deserves attention, especially if buying followed a price decline.
Continue your LXEO research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.